NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as BAUSCH. It is marketed under 1 brand name, including CABTREO. Available in 1 different strength, such as 0.15%;3.1%;1.2%, and administered through 1 route including GEL;TOPICAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"59263","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"62cb2cf4a5b3443f9c5d","publication_number":"US10220049B2","cleaned_patent_number":"10220049","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-03","publication_date":"2019-03-05","legal_status":"Granted"} | US10220049B2 Formulation | 05 Mar, 2019 | Granted | 03 Jun, 2029 | |
| {"application_id":"59264","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"62cb2cf4a5b3443f9c5d","publication_number":"US10624918B2","cleaned_patent_number":"10624918","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-03","publication_date":"2020-04-21","legal_status":"Granted"} | US10624918B2 | 21 Apr, 2020 | Granted | 03 Jun, 2029 | |
| {"application_id":"59260","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"62cb2cf4a5b3443f9c5d","publication_number":"US9561208B2","cleaned_patent_number":"9561208","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-03","publication_date":"2017-02-07","legal_status":"Granted"} | US9561208B2 Formulation | 07 Feb, 2017 | Granted | 03 Jun, 2029 | |
| {"application_id":"59241","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"62cb2cf4a5b3443f9c5d","publication_number":"US8288434B2","cleaned_patent_number":"8288434","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-08-05","publication_date":"2012-10-16","legal_status":"Granted"} | US8288434B2 Formulation | 16 Oct, 2012 | Granted | 05 Aug, 2029 | |
| {"application_id":"117269","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"d5b7f1bcdb3c49ca8fe4","publication_number":"US2022370315A1","cleaned_patent_number":"12128059","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-07-31","publication_date":"2024-10-29","legal_status":"Granted"} | US12128059B2 Formulation | 29 Oct, 2024 | Granted | 31 Jul, 2040 | |
| {"application_id":"138479","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"d5b7f1bcdb3c49ca8fe4","publication_number":"","cleaned_patent_number":"12133859","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-07-31","publication_date":"2024-11-05","legal_status":"Patented case"} | US12133859B2 Formulation | 05 Nov, 2024 | Patented case | 31 Jul, 2040 | |
| {"application_id":"138478","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"d5b7f1bcdb3c49ca8fe4","publication_number":"","cleaned_patent_number":"12138278","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-07-31","publication_date":"2024-11-12","legal_status":"Patented case"} | US12138278B2 Formulation | 12 Nov, 2024 | Patented case | 31 Jul, 2040 | |
| {"application_id":"117261","ingredient":"ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE","trade_name":"CABTREO","family_id":"d5b7f1bcdb3c49ca8fe4","publication_number":"US11389467B2","cleaned_patent_number":"11389467","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-12-28","publication_date":"2022-07-19","legal_status":"Granted"} | US11389467B2 Formulation | 19 Jul, 2022 | Granted | 28 Dec, 2040 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Adapalene; Benzoyl Peroxide; Clindamycin Phosphate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.